{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124293","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.931358+00:00","generated_at":"2026-06-07T16:36:48.059284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Applied DNA Q4 revenue down 78% to $780K; net loss widens to $3.6M","bullets":["Total revenues $780K vs $3.6M YoY; COVID testing contract with CUNY canceled in June 2023.","Gross profit $79K (10% margin) vs $417K (12%) YoY.","Operating loss $4.2M improved slightly from $4.3M; net loss $3.6M vs $665K YoY.","Cash and equivalents $7.2M at Sep 30, 2023, down from $10.8M at Jun 30, 2023.","CEO cites biotherapeutic pivot momentum; GMP capacity expected online H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124293","json":"https://secwatch.observer/filing/0001104659-23-124293.json","markdown":"https://secwatch.observer/filing/0001104659-23-124293.md","text":"https://secwatch.observer/filing/0001104659-23-124293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/0001104659-23-124293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/tm2332417d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:36:48.059284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56555b171d26398581d8250c440600e0c867b9d7","claim":"BNB PLUS CORP. reported fourth quarter ended September 30, 2023 results: revenue approximately $780 thousand, net income $3.6 million.","evidence_excerpt":"in vitro diagnostics, gene editing/therapy and adoptive cell therapy applications.” Summary Fourth Quarter Fiscal 2023 Financial Results: · Total revenues were approximately $780 thousand for the three-month period September 30, 2023, compared to $3.6 million for the same period in the prior fiscal year. The decrease in revenue of approximately $2.8 million was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/0001104659-23-124293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended September 30, 2023"},{"label":"Revenue","value":"approximately $780 thousand"},{"label":"Net income","value":"$3.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}